Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

6.200 +0.190 (+3.16%)
Streaming Delayed Price Updated: 9:31 AM EDT, Apr 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 87,859
Open 6.060
Bid (Size) 6.170 (1,700)
Ask (Size) 6.210 (700)
Prev. Close 6.010
Today's Range 6.060 - 6.200
52wk Range 3.210 - 8.400
Shares Outstanding 103,119,010
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
From Ardelyx, Inc.
Via GlobeNewswire

Performance

YTD
+0.8%
+0.8%
1 Month
+11.7%
+11.7%
3 Month
-21.1%
-21.1%
6 Month
+25.0%
+25.0%
1 Year
+13.8%
+13.8%

More News

Read More
News headline image
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Inc (NASDAQ:ARDX) Reports Q4 2025 Revenue Beat but EPS Miss, Shares Fall ↗
Via Chartmill
Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside — Says Constipation Drug ‘Stole The Show’ With 2026 Guidance ↗
Via Stocktwits
News headline image
Ardelyx President and CEO Sells 41,000 Shares for $243,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug ↗
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? ↗
Via Stocktwits
Topics Earnings Intellectual Property
News headline image
ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time ↗
Via Stocktwits
Topics Artificial Intelligence
News headline image
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Receives New Patent for Tenapanor
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
From Equity Insider
Via GlobeNewswire
News headline image
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? ↗
Via Stocktwits
News headline image
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx (ARDX) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings

Frequently Asked Questions

Is Ardelyx, Inc. - Common Stock publicly traded?
Yes, Ardelyx, Inc. - Common Stock is publicly traded.
What exchange does Ardelyx, Inc. - Common Stock trade on?
Ardelyx, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Ardelyx, Inc. - Common Stock?
The ticker symbol for Ardelyx, Inc. - Common Stock is ARDX on the Nasdaq Stock Market
What is the current price of Ardelyx, Inc. - Common Stock?
The current price of Ardelyx, Inc. - Common Stock is 6.200
When was Ardelyx, Inc. - Common Stock last traded?
The last trade of Ardelyx, Inc. - Common Stock was at 04/30/26 09:31 AM ET
What is the market capitalization of Ardelyx, Inc. - Common Stock?
The market capitalization of Ardelyx, Inc. - Common Stock is 639.34M
How many shares of Ardelyx, Inc. - Common Stock are outstanding?
Ardelyx, Inc. - Common Stock has 639M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.